Glesatinib

From WikiMD's Wellness Encyclopedia

Glesatinib skeletal.svg



Glesatinib (MGCD265) is an experimental anti-cancer drug.[1]

It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).[2]

It is a spectrum selective tyrosine[1] kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".[3]

References[edit | edit source]

External links[edit | edit source]


Glesatinib Resources

Contributors: Prab R. Tumpati, MD